Applied Dna Sciences EBIT

Applied Dna Sciences (APDN) currently reports a EBIT of $-35M as of June 2026. That compares with $-13M in the prior-year period — down 159.5% year over year. That is below the Materials sector average of $15B. Use the charts on this page to explore Applied Dna Sciences's EBIT history and peer comparisons.

Applied Dna Sciences's EBIT decreased from $-13M to $-35M — a 159.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Applied Dna Sciences's EBIT of $-35M is lower than the Materials sector average of $15B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Applied Dna Sciences reported $-35M in EBIT as of June 2026. That compares with $-13M in the prior-year period — down 159.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-35M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Materials average is $15B. From there, open related valuation or income-statement pages for Applied Dna Sciences, and consider following APDN for alerts when major investors trade the stock.